Free Consultation
Patient Portal
A glass dropper dispensing drops of vibrant blue methylene blue liquid into a clear glass of water, creating a blue swirl effect.

What is Methylene Blue? The Science Behind the Blue Liquid

Methylene blue is having a moment right now. I first learned about it in 1998 as a microbiology major at Penn State, where I used it frequently to stain bacterial slides. Today it is getting much more attention, and it’s understandable. It is an actual medication with legitimate uses and has a lot of mechanistic theories that are catchy. It is very cool to “improve mitochondrial health, provide neuroprotection, and reduce free radicals.” Influencers and celebrities are talking about it and recording videos of themselves taking swigs of blue liquid. The biohackers and longevity crowd are having the best time expanding the list of things methylene blue will cure. But how much of this is actually true? Is methylene blue really a miracle medication, or is it just another thing people are pushing to become internet famous and make money? In this post, I am going to get into the details of methylene blue. What is it? What does it really do? Is it safe? The next post will discuss some of the newer theories and the evidence behind them.

The History of Methylene Blue: From Textile Dye to Medicine

Methylene blue is a synthetic dye developed in 1876 by a German chemist named Heinrich Caro for coloring cotton textiles.1 It was later repurposed and became the first fully synthetic compound ever used as a medicine, initially used to treat malaria, psychosis, and seizures.2 In fact, it was the parent compound for the antimalarial drug chloroquine and the phenothiazine antipsychotic drug chlorpromazine.1,2

It has a unique property in that it is a redox-active molecule, which means it can cycle between its oxidized form, methylene blue (MB) which is blue, and its reduced form, leucomethylene blue (LMB), which is colorless. This allows methylene blue to shuttle electrons in biological systems.

Methylene Blue Mechanisms: How It Works at a Cellular Level

Methylene blue has multiple mechanisms of action. Many of them stem from its redox capabilities, but some are from direct binding as well.

Redox Cycling: The Core Property

The primary mechanism of MB is its ability to accept and donate electrons nearly indiscriminately across various biological systems. The oxidized form, MB+, accepts electrons to become LMB, which then donates electrons to various acceptors.2

Cellular Energy: Bypassing the Electron Transport Chain to Produce ATP

Because this is one of the most touted mechanisms of MB in the world of biohacking, I am going to spend some extra time here to explain oxidative phosphorylation. This is the process of producing adenosine triphosphate (ATP) through the electron transport chain.

The electron transport chain is the primary mode of ATP production in the body. It occurs in the mitochondria of every cell. Under normal conditions, electrons are shuttled through complexes I to IV to create a hydrogen gradient, which then allows ATP synthase to produce ATP.

Mitochondrion with an electron transport chain: NADH and FADH2 donate electrons through complexes I–IV, pumping protons to create ATP from ADP. O2 is reduced to H2O at the end of the chain.

Figure 1: The electron transport chain, located in cristae – the infoldings of the inner mitochondrial membrane.

Complex I takes electrons from NADH, supplied by the Krebs cycle, and delivers them to coenzyme Q10 (labeled Q in Figure 1). This process pumps 4 hydrogen ions into the intermembrane space and produces oxygen radicals in the mitochondrial matrix. The NAD produced in this step returns to the Krebs cycle to be used to make more NADH.

Complex II takes electrons from FADH2, also supplied by the Krebs cycle, and delivers them to a separate coenzyme Q10. This step does not produce hydrogen ions but does generate free oxygen radicals in the mitochondrial matrix. The FAD returns to the Krebs cycle to make more FADH2.

Coenzyme Q10 then uses Complex III to transfer electrons to cytochrome C (labeled C in Figure 1). This step pumps 4 more hydrogen ions into the intermembrane space and generates free oxygen radicals in both the intermembrane space and mitochondrial matrix.

Cytochrome C delivers electrons to Complex IV, which pumps 4 more hydrogen ions into the intermembrane space and produces water molecules in the matrix.

The final step is ATP synthase, which uses the energy of the hydrogen ion gradient to convert adenosine diphosphate (ADP) into ATP. Under normal conditions, 1 molecule of NADH produces approximately 2.5 molecules of ATP, and 1 molecule of FADH2 produces approximately 1.5 molecules of ATP.

Methylene blue can bypass the first three steps of the electron transport chain. Because MB can transfer electrons directly from NADH to cytochrome C, fewer oxygen radicals are produced but fewer hydrogen ions accumulate in the intermembrane space as well. The result is only 0.5 molecules of ATP for each molecule of NADH. Below is a figure of methylene blue’s effect on the electron transport chain.

Diagram of a mitochondrion showing electron transport chain complexes I–IV, ATP synthase, proton pumping into the intermembrane space, and the Krebs cycle.

Methemoglobinemia and Restoring Oxygen Delivery

A rare condition called methemoglobinemia oxidizes the iron molecules of hemoglobin, inhibiting the oxygen-carrying capacity of red blood cells. MB acts as a surrogate electron donor, converting the oxidized iron back to its functional state and restoring proper oxygen delivery.3

Nitric Oxide and Monoamine Oxidase A (MOA-A) Inhibition

Nitric oxide (NO) is a gaseous molecule that crosses freely between cell membranes. It plays a central role in blood vessel regulation, neurotransmission, inflammation, cell death, and tumor growth.4 MB inhibits NO production by blocking nitric oxide synthase and guanylate cyclase.5

Monoamine oxidase is a mitochondrial enzyme that breaks down serotonin, dopamine, and norepinephrine. MB inhibits monoamine oxidase A, preventing the breakdown of these monoamine neurotransmitters.2

Epigenetics: Cellular Stress and Nrf2/ARE Pathway

We are getting deep into nerd territory with this one. A few posts back we discussed the difference between genetics and epigenetics. This comes into play here. A protein called Nrf2 (nuclear factor erythroid 2-related factor) is activated in the presence of cellular stress. It travels to the ARE (antioxidant response element) sequence of DNA in certain cell-protecting genes, leading to the production of various antioxidants. MB activates the Nrf2/ARE transcriptional pathway and produces an antioxidant, anti-inflammatory effect.6,7

Protein Aggregation: Inhibiting Tau Clumping in Alzheimer’s Research

Tau is a protein that aggregates with Alzheimer’s disease. There is evidence that MB inhibits tau aggregation.8

Antimalarial Activity: Disrupting the Parasite Life Cycle

MB has been an effective antimalarial agent since the late 19th century. It prevents the parasite from feeding effectively on heme molecules and reduces its reproductive capability.9

Photodynamic Activity: Light Activation and Cellular Death

Under certain wavelengths of light, MB generates a singlet oxygen molecule which induces cellular death.10

Current Medical Uses of Methylene Blue and Dosing Cautions

Methylene blue has several well-established medical uses. It is available as an intravenous solution and as an oral preparation. Methemoglobinemia is the only current FDA-approved use for intravenous MB.3 The oral form of MB is also the oldest synthetic antimalarial drug still in use, administered as part of combination therapy.9 While not FDA-approved, intravenous MB is used in the treatment of refractory septic shock and post-cardiac surgery vasodilatory shock.11 There are also case reports supporting its use in treating encephalopathy in patients receiving ifosfamide-based cancer treatment.12 While these are all documented and evidence-based uses in humans, it is important to know that MB can also be quite toxic.

MB has a well-characterized hormetic dose-response, meaning it produces beneficial effects at low doses and harmful effects at high doses.13 At low doses, LMB predominates and acts as an antioxidant and electron shuttle. At high concentrations, the oxidized form predominates, generating reactive oxygen species that disrupt the electron transport chain’s ability to produce ATP.13

Cell culture and animal model studies suggest up to 2mg/kg intravenously as a therapeutic dose.13 Oral dosing achieves similar concentrations due to the high bioavailability of oral preparations.14 Early signs of toxicity, such as hypotension, wheezing, and reduced oxygen levels, are reported at 3mg/kg doses.15 Doses of 7mg/kg or greater cause methemoglobinemia and are toxic, and doses at 20 mg/kg are fatal.15 What is often overlooked is the fact that MB accumulates with repeat dosing, meaning toxic levels can be reached even when individual doses appear safe.16

Adverse Effects, Contraindications, and FDA Black Box Warnings

Even at therapeutic doses, MB carries serious risks and several black box warnings. This medication is not appropriate for everyone.

Serotonin Syndrome – MB inhibits MOA-A, which allows serotonin to accumulate. Other medications that also increase serotonin levels, such as serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, other monoamine oxidase inhibitors, opioids, and dextromethorphan, can interact with MB to precipitate serotonin syndrome, a potentially fatal condition.16

Hemolytic Anemia in G6PD Deficiency – MB is contraindicated in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency,16 who cannot generate sufficient NADPH. NADPH is an electron carrier in living organisms. Insufficient NADPH in the setting of MB will cause severe hemolysis of red blood cells, compromising the ability to transport oxygen and potentially leading to organ failure and death. It is worth noting that G6PD deficiency is the most common enzyme deficiency worldwide with approximately 500 million people affected.17

There are other concerns that do not meet the level of black warnings as well. Patients with underlying kidney disease are at risk of accumulating toxic medication levels.16 MB can interfere with pulse oximetry readings, so patients who have disease processes that require oxygen monitoring can get falsely low readings. It also may cause birth defects or hemolytic anemia in unborn fetuses with unknown G6PD deficiency, so it is not advised for use in pregnant women.3

What’s Next: Real Clinical Mechanisms vs. Internet Hype

Methylene blue is not a new discovery, and several of its medical applications are well established and evidence-based. But the gap between what MB does in a controlled clinical setting and what influencers are claiming it can do is significant. The mechanisms are real. The question is whether those mechanisms translate into the broad wellness benefits being promoted online and at what dose, in what form, and in whom.

In Part 2, we will get into exactly that. We will look at the proposed longevity uses of methylene blue, examine what the human evidence actually shows versus what comes from cell cultures and animal studies, and discuss the very important differences between pharmaceutical-grade MB and what is being sold online. Because as we have seen before, a real mechanism and a real clinical benefit are not the same thing.

References

  1. Gureev AP, Sadovnikova IS, Popov VN. Molecular Mechanisms of the Neuroprotective Effect of Methylene Blue. Biochemistry (Moscow). 2022/09/01 2022;87(9):940-956. doi:10.1134/S0006297922090073
  2. Tucker D, Lu Y, Zhang Q. From Mitochondrial Function to Neuroprotection-an Emerging Role for Methylene Blue. Mol Neurobiol. Jun 2018;55(6):5137-5153. doi:10.1007/s12035-017-0712-2
  3. Iolascon A, Bianchi P, Andolfo I, et al. Recommendations for diagnosis and treatment of methemoglobinemia. American Journal of Hematology. 2021;96(12):1666-1678. doi:https://doi.org/10.1002/ajh.26340
  4. Andrabi SM, Sharma NS, Karan A, et al. Nitric Oxide: Physiological Functions, Delivery, and Biomedical Applications. Adv Sci (Weinh). Oct 2023;10(30):e2303259. doi:10.1002/advs.202303259
  5. Ballarin RS, Lazzarin T, Zornoff L, et al. Methylene blue in sepsis and septic shock: a systematic review and meta-analysis. Front Med (Lausanne). 2024;11:1366062. doi:10.3389/fmed.2024.1366062
  6. Stack C, Jainuddin S, Elipenahli C, et al. Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity. Hum Mol Genet. Jul 15 2014;23(14):3716-32. doi:10.1093/hmg/ddu080
  7. Li JW, Wang RL, Xu J, et al. Methylene blue prevents osteoarthritis progression and relieves pain in rats via upregulation of Nrf2/PRDX1. Acta Pharmacol Sin. Feb 2022;43(2):417-428. doi:10.1038/s41401-021-00646-z
  8. Huang Y, Wen J, Ramirez LM, et al. Methylene blue accelerates liquid-to-gel transition of tau condensates impacting tau function and pathology. Nat Commun. Sep 6 2023;14(1):5444. doi:10.1038/s41467-023-41241-6
  9. Lu G, Nagbanshi M, Goldau N, et al. Efficacy and safety of methylene blue in the treatment of malaria: a systematic review. BMC Med. Apr 25 2018;16(1):59. doi:10.1186/s12916-018-1045-3
  10. Klosowski EM, de Souza BTL, Mito MS, et al. The photodynamic and direct actions of methylene blue on mitochondrial energy metabolism: A balance of the useful and harmful effects of this photosensitizer. Free Radic Biol Med. Jun 2020;153:34-53. doi:10.1016/j.freeradbiomed.2020.04.015
  11. Prescott HC, Antonelli M, Alhazzanic W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2026. Intensive care medicine. 2026:1-74.
  12. Alqahtani S, Bitar SD, Mireles ME, et al. Ifosfamide-Induced Encephalopathy in Children and Young Adults: The MD Anderson Cancer Center Experience. Cancers (Basel). Jun 29 2025;17(13)doi:10.3390/cancers17132192
  13. Rojas JC, Bruchey AK, Gonzalez-Lima F. Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue. Prog Neurobiol. Jan 2012;96(1):32-45. doi:10.1016/j.pneurobio.2011.10.007
  14. Walter-Sack I, Rengelshausen J, Oberwittler H, et al. High absolute bioavailability of methylene blue given as an aqueous oral formulation. Eur J Clin Pharmacol. Feb 2009;65(2):179-89. doi:10.1007/s00228-008-0563-x
  15. Poteet E, Winters A, Yan LJ, et al. Neuroprotective actions of methylene blue and its derivatives. PLoS One. 2012;7(10):e48279. doi:10.1371/journal.pone.0048279
  16. Inc. ZPU. Methylene Blue Injection. U.S. National Library of Medicine. Updated April 2, 2026. Accessed May 25, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8c56fbad-a449-4ed4-a55f-1694e4e8e26a
  17. Luzzatto L, Ally M, Notaro R. Glucose-6-phosphate dehydrogenase deficiency. Blood. Sep 10 2020;136(11):1225-1240. doi:10.1182/blood.2019000944

Leave a Reply

Discover more from The Whole Human Health & Wellbeing

Subscribe now to keep reading and get access to the full archive.

Continue reading